Cofilin-1 Transgenic Model Using Cre-ERT2 Inducible System
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current animal models primarily focus on cofilin gene knockout for exploring its role, lacking transgenic models for overexpression studies, which hinders the development of inducible expression technology and anti-aging drug screening platforms.
Innovation Solution
The development of tamoxifen-dependent Cre-ERT2 recombinases and Cre-ERT2 transgenic mouse lines enables time- and tissue-specific expression of the cofilin-1 gene using the Cre/lox site-specific recombination system, allowing for controlled overexpression of cofilin-1 in mice.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If cofilin gene knockout is used to explore its role, then the pathophysiological role can be studied, but transgenic models for overexpression studies cannot be developed
Solution Approach 1:
The invention segments the cofilin-1 gene expression control into multiple components: a tissue-specific promoter (Acta2 for smooth muscle, Camk2a for cardiac muscle) and an inducible system (Cre-ERT2). This allows independent control of spatial (tissue-specific) and temporal (tamoxifen-inducible) expression, enabling versatile overexpression studies while maintaining manageable model construction through modular breeding strategies.
2Manufacturing precision
If constitutive transgenic expression is used, then overexpression can be achieved, but temporal and spatial control is lost
Solution Approach 1:
The invention implements dynamic control of cofilin-1 expression through the Cre-ERT2 system. The expression level and timing are adjusted by controlling tamoxifen administration, allowing researchers to induce expression at specific developmental stages or in response to experimental conditions. This dynamic control provides precise spatiotemporal regulation while maintaining research efficiency through a single transgenic line that can be activated as needed.
3Reliability
If inducible Cre-ERT2 system is used, then temporal control is achieved, but system complexity increases
Solution Approach 1:
The invention uses Cre-ERT2 as an intermediary component that mediates between the tamoxifen signal and the cofilin-1 expression. The Cre-ERT2 recombinase acts as a molecular switch that remains inactive until tamoxifen binding triggers its activation. This intermediary mechanism provides reliable temporal control while managing system complexity through well-established Cre-loxP recombination technology that can be integrated with existing tissue-specific promoters.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for precise temporal and spatial regulation of cofilin-1 expression, enabling the creation of a reliable transgenic model for studying its pathophysiological role and facilitating anti-aging drug screening.
Implementation Method 1
the Cre/lox site-specific recombination system has emerged as an important tool for the generation of conditional somatic mouse mutants
Data Source
AI summary
The present invention demonstrated a Cre-loxP based cofilin-1 transgenic animal model to address the pathophysiological role of over-expressed cofilin-1 on systemic development.